Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Allergan

Celgene

Eli Lilly

Merck

Pfizer

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

Black Stone Minerals LP

Carnival

Iron Mountain

Kroger

Simon Property Group

According to GuruFocus’ list of 52-week lows, these Guru stocks have reached their 52-week lows.

52-Week Company Lows (June 30)

Some of the drugs aren't going to survive this marriage.

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Bristol-Myers Squibb’s  (NYSE:BMY) oncology drugs business is its largest therapeutic area, and it will likely grow in mid-single-digits from about $10.3 billion in 2018 to $12.4 billion in 2021, according to Trefis estimates. This growth will likely be driven by higher sales of Opdivo.

How Does Bristol-Myers Squibb's Oncology Drugs Portfolio Compare To Its Peers?

Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

Bad news comes in threes for Bristol-Myers and Celgene.

Bristol-Myers Squibb had some bad news for investors

Caesars Entertainment

Match Group

New Relic

Bristol-Myers Squibb, Celgene, Caesars Entertainment, Match Group and New Relic are our top stock trades for Tuesday.

5 Top Stock Trades for Tuesday

The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug.

Bristol-Myers deal to acquire Juno parent Celgene delayed amid FTC concerns

Shares of Bristol-Myers Squibb plunged Monday after announcing that the target closing date for the proposed acquisition of Celgene has been pushed back and that the deal will include a divestiture of Otezla, a psoriasis drug.

Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment

Bristol-Meyers Squibb news for Monday has BMY stock taking a beating after announcing a delay to its merger deal with Celgene.
The post Bristol-Meyers Squibb News: Why BMY Stock Is Falling Today appeared first on InvestorPlace.

Bristol-Meyers Squibb News: Why BMY Stock Is Falling Today

Uncertainty over Bristol-Myers Squibb Co (NYSE: BMY)'s impending deal to acquire Celgene Corporation (NASDAQ: CELG) and an adverse clinical trial readout were dragging the shares of the large-cap pharma company lower Monday.

Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

Celgene will have to divest its blockbuster drug Otezla in order to satisfy drug regulators before completing its merger with Bristol-Myers Squibb, the biopharma companies said Monday.
The post Bristol-Myers Plans To Divest Celgene Blockbuster To Satisfy Regulators appeared first on Investor's Business Daily.

Bristol-Myers Plans To Divest Celgene Blockbuster To Satisfy Regulators

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co. BMY, +0.92% said Monday a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals.

Bristol-Myers offers update on liver cancer trial, to sell Otzela to hasten close of Celgene deal

Bristol-Myers Squibb announced its plan to acquire Celgene more than 6 months ago. The deal has since been approved by shareholders from both companies.

Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination

Shareholders get an all-or-nothing $9 contingent value right (CVR) when the acquisition closes.

What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?

Amgen

Gilead Sciences

Johnson & Johnson

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

Big Drugmakers That May Tread the M&A Path After Pfizer

Bristol-Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock?

Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.

5 Biggest Blockbuster Drugs of the Future

These big pharma stocks all have a Zacks Rank #2 or better.

3 Big Pharma Stocks to Buy Right Now

Analysts at UBS cut their price target on shares of Bristol-Myers Squibb Co. BMY, +1.62% on Thursday to $51 from $55 per share, citing lower-than-consensus expectations for the company's immuno-oncology franchise.

Price target on Bristol-Myers stock cut to $51 at UBS

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Sees a Rising Tide in Short Interest

Novartis

Vertex Pharmaceuticals

New blockbusters could be on the way for five drugmakers.

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Northrop Grumman

PepsiCo

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate

Synovus Financial

MMM stock has fallen 25% in the past six weeks since announcing weaker-than-expected Q1 earnings. 3M stock has been weak since then.

News for Bristol-Myers Stock (BMY)